This study investigates gastroenteropancreatic neuroendocrine tumors. The purpose of this study is to evaluate the effectiveness of peptide receptor radionuclide therapy after surgical removal of tumor tissue.
The study evaluates the response rate, safety, and tolerability of this treatment approach. It also looks at the characteristics of the tumors and their response to therapy.
- Who can participate: Participants must be 18 years or older with well-differentiated grade 1 or 2 gastroenteropancreatic neuroendocrine tumors. They must have a somatostatin receptor-positive tumor and hepatic metastasis.
- Study details: Participants will undergo surgery to remove as much of the tumor as possible. After surgery, they will receive an investigational medication that targets tumor cells. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand